Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isavuconazonium - Basilea Pharmaceutica

Drug Profile

Isavuconazonium - Basilea Pharmaceutica

Alternative Names: AK-1820; ASP-9766; BAL-8557; BAL-8557-000; BAL-8557-002; BAL-9557; Cresemba; isavuconasole; Isavuconazole - Basilea Pharmaceutica; Isavuconazonium chloride; Isavuconazonium sulfate; Isavuconazonium sulphate

Latest Information Update: 12 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; Avir Pharma; Basilea Pharmaceutica; Grupo Biotoscana; Hikma Pharmaceuticals; Pfizer
  • Class Antifungals; Antineoplastics; Fluorinated hydrocarbons; Inorganic sulfur compounds; Nitriles; Pyridines; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis; Candidiasis; Candidaemia; Zygomycosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Invasive bronchopulmonary aspergillosis; Zygomycosis
  • Phase III Candidiasis; Mycoses
  • No development reported Haematological malignancies

Most Recent Events

  • 12 Feb 2021 Launched for Zygomycosis in South Korea (IV) (Basilea Pharmaceutica pipeline, February 2021)
  • 09 Feb 2021 Launched for Invasive bronchopulmonary aspergillosis in South Korea (IV) (Basilea Pharmaceutica pipeline, February 2021)
  • 09 Feb 2021 Launched for Invasive bronchopulmonary aspergillosis in South Korea (PO) (Basilea Pharmaceutica pipeline, February 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top